Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents

Science

Volumn 281, Issue 5374, 1998, Pages 266-269

  Poon, Betty ^a   Grovit Ferbas, Kathie ^a   Stewart, Sheila A ^a   Chen, Irvin S Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ARTICLE; CELL CYCLE; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; T LYMPHOCYTE; VIRION; VIRUS GENE; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIGENS, THY-1; G2 PHASE; GENE PRODUCTS, VPR; GENES, REPORTER; GENES, VPR; HELA CELLS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; LEUKOCYTES; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; VIRION; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032504065     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.281.5374.266     Document Type: Article

References (58)

1. X. F. Yu, S. Ito, M. Essex, T. H. Lee, Nature 335, 262 (1988); E. A. Cohen, G. Dehni, J. G. Sodroski, W. A. Haseltine, J. Virol. 64, 3097 (1990); X. F. Yu, M. Matsuda, M. Essex, T. H. Lee, ibid., p. 5688; X. Yuan, Z. Matsuda, M. Matsuda, M. Essex, T. H. Lee, AIDS Res. Hum. Retroviruses 6, 1265 (1990).
2. X. F. Yu, S. Ito, M. Essex, T. H. Lee, Nature 335, 262 (1988); E. A. Cohen, G. Dehni, J. G. Sodroski, W. A. Haseltine, J. Virol. 64, 3097 (1990); X. F. Yu, M. Matsuda, M. Essex, T. H. Lee, ibid., p. 5688; X. Yuan, Z. Matsuda, M. Matsuda, M. Essex, T. H. Lee, AIDS Res. Hum. Retroviruses 6, 1265 (1990).
3. X. F. Yu, S. Ito, M. Essex, T. H. Lee, Nature 335, 262 (1988); E. A. Cohen, G. Dehni, J. G. Sodroski, W. A. Haseltine, J. Virol. 64, 3097 (1990); X. F. Yu, M. Matsuda, M. Essex, T. H. Lee, ibid., p. 5688; X. Yuan, Z. Matsuda, M. Matsuda, M. Essex, T. H. Lee, AIDS Res. Hum. Retroviruses 6, 1265 (1990).
4. X. F. Yu, S. Ito, M. Essex, T. H. Lee, Nature 335, 262 (1988); E. A. Cohen, G. Dehni, J. G. Sodroski, W. A. Haseltine, J. Virol. 64, 3097 (1990); X. F. Yu, M. Matsuda, M. Essex, T. H. Lee, ibid., p. 5688; X. Yuan, Z. Matsuda, M. Matsuda, M. Essex, T. H. Lee, AIDS Res. Hum. Retroviruses 6, 1265 (1990).
5. K. Ogawa et al., J. Virol. 63, 4110 (1989); N. Hattori et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8080 (1990); P. Westervelt et al., J. Virol. 66, 3925 (1992); C. P. Balotta, P. Lusso, R. Crowley, R. C. Gallo, C. Franchini, J. Exp. Med. 176, 1099 (1993); J. W. Balliet et al., Virology 200, 623 (1994); R. I. Connor, B. K. Chen, S. Choe, N. R. Landau, ibid. 206, 935 (1995).
6. K. Ogawa et al., J. Virol. 63, 4110 (1989); N. Hattori et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8080 (1990); P. Westervelt et al., J. Virol. 66, 3925 (1992); C. P. Balotta, P. Lusso, R. Crowley, R. C. Gallo, C. Franchini, J. Exp. Med. 176, 1099 (1993); J. W. Balliet et al., Virology 200, 623 (1994); R. I. Connor, B. K. Chen, S. Choe, N. R. Landau, ibid. 206, 935 (1995).
7. K. Ogawa et al., J. Virol. 63, 4110 (1989); N. Hattori et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8080 (1990); P. Westervelt et al., J. Virol. 66, 3925 (1992); C. P. Balotta, P. Lusso, R. Crowley, R. C. Gallo, C. Franchini, J. Exp. Med. 176, 1099 (1993); J. W. Balliet et al., Virology 200, 623 (1994); R. I. Connor, B. K. Chen, S. Choe, N. R. Landau, ibid. 206, 935 (1995).
8. K. Ogawa et al., J. Virol. 63, 4110 (1989); N. Hattori et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8080 (1990); P. Westervelt et al., J. Virol. 66, 3925 (1992); C. P. Balotta, P. Lusso, R. Crowley, R. C. Gallo, C. Franchini, J. Exp. Med. 176, 1099 (1993); J. W. Balliet et al., Virology 200, 623 (1994); R. I. Connor, B. K. Chen, S. Choe, N. R. Landau, ibid. 206, 935 (1995).
9. K. Ogawa et al., J. Virol. 63, 4110 (1989); N. Hattori et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8080 (1990); P. Westervelt et al., J. Virol. 66, 3925 (1992); C. P. Balotta, P. Lusso, R. Crowley, R. C. Gallo, C. Franchini, J. Exp. Med. 176, 1099 (1993); J. W. Balliet et al., Virology 200, 623 (1994); R. I. Connor, B. K. Chen, S. Choe, N. R. Landau, ibid. 206, 935 (1995).
10. K. Ogawa et al., J. Virol. 63, 4110 (1989); N. Hattori et al., Proc. Natl. Acad. Sci. U.S.A. 87, 8080 (1990); P. Westervelt et al., J. Virol. 66, 3925 (1992); C. P. Balotta, P. Lusso, R. Crowley, R. C. Gallo, C. Franchini, J. Exp. Med. 176, 1099 (1993); J. W. Balliet et al., Virology 200, 623 (1994); R. I. Connor, B. K. Chen, S. Choe, N. R. Landau, ibid. 206, 935 (1995).
11. N. K. Heinzinger et al., Proc. Natl. Acad. Sci. U.S.A. 91, 7311 (1994).
12. S. M. Lang et al., J. Virol. 67, 902 (1993); J. S. Gibbs et al., ibid. 69, 2378 (1995); J. Hoch et al., ibid., p. 4807.
13. S. M. Lang et al., J. Virol. 67, 902 (1993); J. S. Gibbs et al., ibid. 69, 2378 (1995); J. Hoch et al., ibid., p. 4807.
14. S. M. Lang et al., J. Virol. 67, 902 (1993); J. S. Gibbs et al., ibid. 69, 2378 (1995); J. Hoch et al., ibid., p. 4807.
15. E. A. Cohen et al., J. AIDS 3, 11 (1990); D. N. Levy, Y. Refaeli, R. R. Williams, D. B. Weiner, Proc. Natl. Acad. Sci. U.S.A. 91, 10873 (1994); W. C. Goh et al., Nature Med. 4, 65 (1998); R. A. Subbramanian et al., J. Exp. Med. 7, 1103 (1998).
16. E. A. Cohen et al., J. AIDS 3, 11 (1990); D. N. Levy, Y. Refaeli, R. R. Williams, D. B. Weiner, Proc. Natl. Acad. Sci. U.S.A. 91, 10873 (1994); W. C. Goh et al., Nature Med. 4, 65 (1998); R. A. Subbramanian et al., J. Exp. Med. 7, 1103 (1998).
17. E. A. Cohen et al., J. AIDS 3, 11 (1990); D. N. Levy, Y. Refaeli, R. R. Williams, D. B. Weiner, Proc. Natl. Acad. Sci. U.S.A. 91, 10873 (1994); W. C. Goh et al., Nature Med. 4, 65 (1998); R. A. Subbramanian et al., J. Exp. Med. 7, 1103 (1998).
18. E. A. Cohen et al., J. AIDS 3, 11 (1990); D. N. Levy, Y. Refaeli, R. R. Williams, D. B. Weiner, Proc. Natl. Acad. Sci. U.S.A. 91, 10873 (1994); W. C. Goh et al., Nature Med. 4, 65 (1998); R. A. Subbramanian et al., J. Exp. Med. 7, 1103 (1998).
19. M. E. Rogel, L. I. Wu, M. Emerman, J. Virol. 69, 882 (1995).
20. J. He et al., ibid., p. 6705; F. Re, D. Braaten, E. K. Franke, J. Luban, ibid., p. 6859.
21. J. He et al., ibid., p. 6705; F. Re, D. Braaten, E. K. Franke, J. Luban, ibid., p. 6859.
22. J. B. M. Jowett et al., ibid., p. 6304.
23. B. Poon et al., ibid. 71, 3961 (1997).
24. S. Stewart, B. Poon, J. B. M. Jowett, I. S. Y. Chen, ibid., p. 5579.
25. B. Poon and I. S. Y. Chen, unpublished observations.
26. NL4-3-thy env(-)vprX + BSVpr were generated after transfection with BSVpr [V. Planelles et al., J. Virol. 70, 2516 (1996)], pCMV-VSV-G, and NLthyΔBglVprX.
27. NL4-3-thy env(-)vprX + BSVpr were generated after transfection with BSVpr [V. Planelles et al., J. Virol. 70, 2516 (1996)], pCMV-VSV-G, and NLthyΔBglVprX.
28. + cells compared with mock-infected cells (0.43 and 1.7, respectively).
29. + cells compared with mock-infected cells (0.43 and 1.7, respectively).
30. 2 ratio compared with mock-infected cells (1.4 and 2.4, respectively).
31. 2 ratio of 0.15.
32. - cells compared with mock-infected cells (0.66 and 0.76 and 1.4, respectively).
33. H. Mitsuya et al., Proc. Natl. Acad. Sci. U.S.A. 82, 7096 (1985); V. J. Merluzzi et al., Science 250, 1411 (1990).
34. H. Mitsuya et al., Proc. Natl. Acad. Sci. U.S.A. 82, 7096 (1985); V. J. Merluzzi et al., Science 250, 1411 (1990).
35. 2 ratios of 1.64, 1.27, and 1.35, respectively, compared with 1.75 for non-RTI-treated cells. Virions pseudotyped with HIV-1 envelope were obtained after transfection with NLthyΔBgl or NLthyΔBglVprX and pLET-LAI. Supernatant was collected 48 hours after transfection and concentrated by ultracentrifugation at 40,000g for 1 hour.
36. T. J. McQuade et al., Science 247, 454 (1990); T. D. Meek et al., Nature 343, 90 (1990); N. A. Roberts et al., Science 248, 358 (1990).
37. T. J. McQuade et al., Science 247, 454 (1990); T. D. Meek et al., Nature 343, 90 (1990); N. A. Roberts et al., Science 248, 358 (1990).
38. T. J. McQuade et al., Science 247, 454 (1990); T. D. Meek et al., Nature 343, 90 (1990); N. A. Roberts et al., Science 248, 358 (1990).
39. Virus produced in the presence of PI was obtained after transfection with either NLthyΔBglVprX or NLthyΔBgl and pCMV-VSV-G. At 24 hours after transfection, the medium was replaced with medium containing 100 nM indinavir sulfate (Merck). Supernatant was collected 48 and 72 hours after transfection and concentrated (9).
40. J. Kimpton and M. Emerman, J. Virol. 66, 2232 (1992); S. P. Layne et al., Virology 189, 695 (1992).
41. J. Kimpton and M. Emerman, J. Virol. 66, 2232 (1992); S. P. Layne et al., Virology 189, 695 (1992).
42. M. Piatak, Jr. et al., Science 259, 1749 (1993); T.-W. Chun et al., Nature 387, 183 (1997).
43. M. Piatak, Jr. et al., Science 259, 1749 (1993); T.-W. Chun et al., Nature 387, 183 (1997).
44. V. Ayyavoo et al., Nature Med. 3, 1117 (1997).
45. K. Tenner-Racz et al., in Progress in AIDS Pathology, H. Rotterdam and S. C. Sommers, Eds. (Field and Wood, New York, 1989), pp. 29-40; J. Embretson et al., Nature 362, 359 (1993); C. Pantaleo et al., ibid., p. 355.
46. K. Tenner-Racz et al., in Progress in AIDS Pathology, H. Rotterdam and S. C. Sommers, Eds. (Field and Wood, New York, 1989), pp. 29-40; J. Embretson et al., Nature 362, 359 (1993); C. Pantaleo et al., ibid., p. 355.
47. K. Tenner-Racz et al., in Progress in AIDS Pathology, H. Rotterdam and S. C. Sommers, Eds. (Field and Wood, New York, 1989), pp. 29-40; J. Embretson et al., Nature 362, 359 (1993); C. Pantaleo et al., ibid., p. 355.
48. G. M. Shearer et al., J. Immunol. 137, 2515 (1986); B. Wahren et al., J. Virol. 61, 2017 (1987).
49. G. M. Shearer et al., J. Immunol. 137, 2515 (1986); B. Wahren et al., J. Virol. 61, 2017 (1987).
50. J. K. Wong et al., Science 278, 1291 (1997); D. Finzi et al., ibid., p. 1295; J. K. Wong et al., Proc. Natl. Acad. Sci. U.S.A. 94, 12574 (1997), T.-W. Chun et al., ibid., p. 13193.
51. J. K. Wong et al., Science 278, 1291 (1997); D. Finzi et al., ibid., p. 1295; J. K. Wong et al., Proc. Natl. Acad. Sci. U.S.A. 94, 12574 (1997), T.-W. Chun et al., ibid., p. 13193.
52. J. K. Wong et al., Science 278, 1291 (1997); D. Finzi et al., ibid., p. 1295; J. K. Wong et al., Proc. Natl. Acad. Sci. U.S.A. 94, 12574 (1997), T.-W. Chun et al., ibid., p. 13193.
53. J. K. Wong et al., Science 278, 1291 (1997); D. Finzi et al., ibid., p. 1295; J. K. Wong et al., Proc. Natl. Acad. Sci. U.S.A. 94, 12574 (1997), T.-W. Chun et al., ibid., p. 13193.
54. B. Autran et al., Science 277, 112 (1997); M. Connors et al., Nature Med. 3, 533 (1997).
55. B. Autran et al., Science 277, 112 (1997); M. Connors et al., Nature Med. 3, 533 (1997).
56. Concentrated virus was lysed in 2× loading buffer and subjected to electrophoresis on SDS-15% polyacrylamide gels (9). Western blotting was performed with a rabbit polyclonal antibody for Vpr (provided by N. Landau, Aaron Diamond AIDS Research Center, New York) or human anti-HIV hyperimmune plasma (provided by P. Krogstad and Y. Bryson, UCLA) and developed with the enhanced chemiluminescence assay (Amersham, Arlington Heights, IL).
57. The method of double staining for surface marker Thy 1.2 and DNA content was performed as described in (9, 10). All stained cells were acquired on a FACScan II apparatus (Becton-Dickinson) and analyzed with Cell Quest software.
58. We thank D. S. An, J. Zack, and P. Krogstad for valuable reagents and advice and Vaheideh Gudeman for technical support. Supported by NIH grant CA70018 and Center for AIDS Research grant AI28697. B.P. and K.G.-F. were supported by NIH postdoctoral training grant T32/A107388.